- Home
- KLRS vs CNTB Comparison
KLRS vs CNTB Comparison
Compare KLRS & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- CNTB
- Stock Information
- Founded
- KLRS 2019
- CNTB 2012
- Country
- KLRS United States
- CNTB United States
- Employees
- KLRS N/A
- CNTB N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- CNTB Biotechnology: Pharmaceutical Preparations
- Sector
- KLRS Health Care
- CNTB Health Care
- Exchange
- KLRS Nasdaq
- CNTB Nasdaq
- Market Cap
- KLRS 46.0M
- CNTB 54.4M
- IPO Year
- KLRS N/A
- CNTB 2021
- Fundamental
- Price
- KLRS $2.56
- CNTB $1.73
- Analyst Decision
- KLRS Buy
- CNTB Strong Buy
- Analyst Count
- KLRS 1
- CNTB 2
- Target Price
- KLRS N/A
- CNTB $7.50
- AVG Volume (30 Days)
- KLRS 45.1K
- CNTB 142.0K
- Earning Date
- KLRS 08-13-2025
- CNTB 08-13-2025
- Dividend Yield
- KLRS N/A
- CNTB N/A
- EPS Growth
- KLRS N/A
- CNTB N/A
- EPS
- KLRS N/A
- CNTB N/A
- Revenue
- KLRS N/A
- CNTB $1,965,000.00
- Revenue This Year
- KLRS N/A
- CNTB N/A
- Revenue Next Year
- KLRS N/A
- CNTB N/A
- P/E Ratio
- KLRS N/A
- CNTB N/A
- Revenue Growth
- KLRS N/A
- CNTB N/A
- 52 Week Low
- KLRS $2.14
- CNTB $0.51
- 52 Week High
- KLRS $24.15
- CNTB $2.86
- Technical
- Relative Strength Index (RSI)
- KLRS 49.38
- CNTB 45.23
- Support Level
- KLRS $2.37
- CNTB $1.60
- Resistance Level
- KLRS $2.58
- CNTB $1.86
- Average True Range (ATR)
- KLRS 0.18
- CNTB 0.24
- MACD
- KLRS 0.01
- CNTB -0.07
- Stochastic Oscillator
- KLRS 64.32
- CNTB 15.12
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.